Abstracts tagged "treatment"

Abstract Number: 2776 • 2015 ACR/ARHP Annual Meeting
Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection
Jason Ptacek, Ellen L. Berg and Alison O'Mahony, BioSeek, a division of DiscoveRx Corp., South San Francisco, CA
Background/Purpose: In vitro co-cultures of human primary cells, including immune cells, fibroblasts, smooth muscle, keratinocytes, epithelial or endothelial cells were developed to capture the complexity…
Abstract Number: 611 • 2015 ACR/ARHP Annual Meeting
The Rapid Kinetics of Optimal Treatment with Subcutaneous Methotrexate in Early Inflammatory Arthritis
Anna O'Connor¹, J Carter Thorne², Diane Tin³ and Janet E. Pope⁴, ¹Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: Methotrexate (MTX) is standard treatment in RA. Absorption is better in subcutaneous MTX (scMTX), which may impact speed of onset. In RA, earlier time…
Abstract Number: 2783 • 2015 ACR/ARHP Annual Meeting
What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort
Edward C. Keystone¹, Mohammad Movahedi^2,3, Angela Cesta², Xiuying Li², Sandra Couto², Emmanouil Rampakakis³, John S. Sampalis^3,4, Claire Bombardier^2,5,6 and OBRI Investigators, ¹The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Although the majority of RA patients respond to treatment with anti-TNF agents, some patients present with refractory disease (1ry failure) while others show some…
Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting
Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
T. W. J. Huizinga¹, Anastas Batalov², Rumen Stoilov³, Eric Lloyd⁴, Thomas Wagner⁵, Didier Saurigny⁶, Bernard Souberbielle⁶ and Ehsanollah Esfandiari⁶, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²UMHAT Kaspela, Plovdiv, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Takeda Pharmaceuticals, Deerfield, IL, ⁵Takeda Pharmaceuticals, Zurich, Switzerland, ⁶Takeda Pharmaceuticals, London, United Kingdom
Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…
Abstract Number: 3194 • 2015 ACR/ARHP Annual Meeting
Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Michael Schiff¹ and Peter Sadowski², ¹Division of Rheumatology, University of Colorado, Denver, CO, ²Antares Pharma Inc., Minneapolis, MN
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy1 but absorption saturation limitations compromise oral MTX bioavailability (BA). Subcutaneous (SC) MTX has a…
Abstract Number: 970 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study
Roy Fleischmann¹, Geraldo Castelar-Pinheiro², Jan Brzezicki³, Pawel Hrycaj⁴, Yong Lin⁵, Janet van Adelsberg⁶, Neil Graham⁷, Hubert van Hoogstraten⁵, Deborah Bauer⁵ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ³Centrum Kliniczno-Badawcze, Elblag, Poland, ⁴Poznan University of Medical Sciences, Poznan, Poland, ⁵Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. The phase 3 MOBILITY study (NCT01061736) evaluated the efficacy and safety…
Abstract Number: 3243 • 2015 ACR/ARHP Annual Meeting
A Randomized Controlled Trial for a Physical Activity Intervention for RA Fatigue
Patricia P. Katz¹, Mary Margaretten², Steven Gregorich¹, Sandi Kaplan³, Stephanie Rush⁴ and Laura Trupin¹, ¹Medicine, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Fatigue is a major problem for people with RA. Physical inactivity is an indirect risk factor for fatigue1. We tested the effect of a…
Abstract Number: 1280 • 2015 ACR/ARHP Annual Meeting
Comparison of Health Service Utilization Costs Between Aboriginal and Non-Aboriginal Patients with Rheumatoid Arthritis Requiring Biologic Therapy
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Logistical issues and poor cultural environments in tertiary care create barriers to specialized care for Aboriginal patients with rheumatoid arthritis (RA). Aboriginal patients are…
Abstract Number: 1318 • 2015 ACR/ARHP Annual Meeting
Prediction of Large Joint Destruction in Patients with Rheumatoid Arthritis Using FDG-PET/CT: A Prospective Study
Takahito Suto, Koichi Okamura, Yukio Yonemoto, Chisa Okura and Kenji Takagishi, Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Background/Purpose: The assessments of joint damage in patients with rheumatoid arthritis (RA) are mainly restricted to small joints in the hands and feet. However, the…
Abstract Number: 1438 • 2015 ACR/ARHP Annual Meeting
Oral Potassium (K+) Reduces Pain in RA: A Randomized Active Control Study of Diet Based K+ Intervention
Toktam Kainifard¹, Manjit Saluja², Anuradha Venugopalan³, Raju Rane⁴ and Arvind Chopra⁵, ¹Rheumatology, PhD fellow, Pune, India, ²Clinical care, Center for Rheumatic Diseases, Pune, India, ³Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, ⁴Pathology, Pathologist, Pune, India, ⁵Rheumatology, Centre for Rheumatic Diseases, Pune 411001, India
Background/Purpose: National Health and Nutrition Survey III (1988-94,USA) data showed a low K+ body status in RA. Further information is scanty. K+ is critical to…
Abstract Number: 1632 • 2015 ACR/ARHP Annual Meeting
Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Improved means to predict which RA patients will respond to methotrexate monotherapy, the preferred first line therapy in early RA, would allow patients to…
Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Kara Bickham¹, Désirée van der Heijde², Narinder Rawal³, Joachim Sieper⁴, Boyd Scott⁵, Nancy Frontera¹, Sandhya Shah¹, Paul Stryszak¹, Dimitris Papanicolaou¹, Zoran Popmihajlov¹ and Paul Peloso¹, ¹Merck & Co., Inc., Kenilworth, NJ, ²University Hospital, Maastricht, Netherlands, ³Orebro University Hospital, Orebro, Sweden, ⁴Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…
Abstract Number: 1659 • 2015 ACR/ARHP Annual Meeting
Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA
Lisa K. Stamp¹, Jill Drake², John L. O'Donnell³, Christopher Frampton⁴ and Peter T. Chapman⁵, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Immunology, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵Rheumatology, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: It is recommended that all patients receiving MTX also receive at least 5mg/week of folic acid in an effort to reduce occurrence of MTX…
Abstract Number: 1660 • 2015 ACR/ARHP Annual Meeting
Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy
M. Victoria Hernández¹, Jose Inciarte-Mundo², Sonia Cabrera-Villalba³, Virginia Ruiz-Esquide⁴, Julio Ramirez², Andrea Cuervo⁴, Juan D. Cañete^4,5 and Raimon Sanmarti², ¹Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ²Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ⁴Arthritis Unit. Rheumatology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clinic, Barcelona, Arthritis Unit, Rheumatology Department, Barcelona, Spain
Background/Purpose: Dose reduction of biological therapy in patients with chronic arthritis (CA) with good clinical response is a common pattern in clinical practice. However, most…
Abstract Number: 1665 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Mohammad Movahedi^2,3, Angela Cesta², Xiuying Li², Sandra Couto², Emmanouil Rampakakis³, John S. Sampalis^3,4, Claire Bombardier^2,5,6 and OBRI Investigators, ¹University of Western Ontario, London, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Guidelines support the use of combination conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs), switching csDMARDs and/or use of biologic DMARDs (bDMARDs) treatment in active rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.